News

In conjunction with the research agreement, Ziopharm also signed a two-year option agreement to enter into an exclusive worldwide license agreement for these novel alkylating agents. A patent

The updated product label comes as a follow-up to the letter issued to healthcare providers in August 2004 regarding an increased risk of arterial thromboembolic events (ATEs) associated

The primary objective of the multi-center, open-label, non-randomized phase II trial is to evaluate tumor response (the level of anti-tumor activity of EOquin), with time to recurrence and

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has jointly developed these principles of disclosure together with three other industry associations: the European Federation of Pharmaceutical Industries

At merger, the enlarged company will have cash reserves of GBP11 million, approximately half of which is new investment secured from existing investors, Bio-1 Capital, Merlin Biosciences and

The investigator-initiated study, which was published in medical journal The Lancet, is the largest clinical trial to date with peginterferon alfa-2b therapy (PegIntron) for chronic hepatitis B. “Our

The alpha interferon, BLX-883, will be the first product manufactured using Biolex’ proprietary LEX System to enter the clinic. The study is designed to evaluate safety, pharmacokinetics and

Actilon is a first-in-class Toll-like receptor 9 (TLR9) agonist initially being developed for the treatment of hepatitis C. The phase Ia trial of Actilon in 40 healthy volunteers

Traficet-EN is a novel, orally bioavailable, anti-inflammatory agent that targets the chemokine receptor known as CCR9. The receptor is on gut-homing inflammatory cells that are responsible for the